Vaccinia virus is the prototypical member of the family Poxviridae. Three morphologically distinct forms are produced during infection: intracellular mature virions (IMV), intracellular enveloped virions (IEV), and extracellular enveloped virions (EEV). Two viral proteins, F12 and A36, are found exclusively on IEV but not on IMV and EEV. Analysis of membranes from infected cells showed that F12 was only associated with membranes and is not an integral membrane protein. A yeast two-hybrid assay revealed an interaction between amino acids 351 to 458 of F12 and amino acids 91 to 111 of A36. We generated a recombinant vaccinia virus that expresses an F12, which lacks residues 351 to 458. Characterization of this recombinant revealed a small-plaque phenotype and a subsequent defect in virus release similar to a recombinant virus that had F12L deleted. In addition, F12 lacking residues 351 to 458 was unable to associate with membranes in infected cells. These results suggest that F12 associates with IEV through an interaction with A36 and that this interaction is critical for the function of F12 during viral egress.
The following day, cells were harvested by scraping, lysed by freeze-thawing, and single-crossover recombinants were selected for by infecting BS-C-1 cells in the presence of xanthine (250 g/ml), hypoxanthine (15 g/ml), and mycophenolic acid (25 g/ml) . Plaques that fluoresced both green and red were picked and plaque purified three more times in the presence of selection. Subsequent plaque purification was performed four additional times in the absence of selection, with non-red plaques being picked each time. The recombinant viruses produced were amplified to high titer, and insertion of the recombinant DNA into the genome was verified via PCR and sequencing.
vB5R-GFP/F12L-HA was generated as follows. HeLa cells were infected with vB5R-GFP/⌬F12L and transfected with pF12L-HA-118 by using Lipofectamine (Invitrogen) according to the manufacturer's instructions. At 24 h p.i., cells were harvested and lysed by freeze-thawing, and the lysate was used to infect BS-C-1 cells. Plaques that fluoresced green were purified a total of four times on BS-C-1 cells. The recombinant virus was amplified and verified by PCR and sequencing.
Yeast two-hybrid constructs and assay. Plasmids expressing the GAL4 DNAbinding domain (BD) fused to the cytoplasmic domains of A33, A34, B5, and various regions of A36 (A33 81-111 -BD, and A36 91-111 -BD, respectively) were a gift from Bernard Moss and have been previously described (23) . Plasmids that encode various regions of F12 fused to the GAL4 activation domain (AD) in pGADT7 (BD Biosciences Clontech) were constructed by amplifying the desired regions of F12L by PCR so that a 5Ј NdeI and a 3Ј EcoRI restriction endonuclease site was added. Amplified fragments were initially inserted into pGEM-T (Promega) and verified by sequencing. They were subsequently inserted in pGADT7 by using standard molecular biology techniques. The plasmids were named pGAD-F12L , pGAD-F12L
125-348 , pGAD-F12L , and pGAD-F12L . Plasmids were transformed into yeast strain AH109 and assayed for interaction as previously described (23) .
In vitro interaction assay. The purification of GST-A36R has been previously described (20) . In vitro transcription and translation of pGAD-F12L and pGAD-F12L in the presence of [ 35 S]methionine-cysteine was performed by using the TNT quick-coupled transcription/translation system (Promega). Equal amounts of the products were subsequently incubated with purified glutathione S-transferase (GST) alone or GST-A36 that had been bound to glutathione-Sepharose 4B beads (Amersham Pharmacia) in lysis buffer (25 mM Tris [pH 8], 0.5 M NaCl, 10 mM EDTA) as previously described (16) . The beads were washed and resuspended in protein loading buffer. Protein complexes were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose, and visualized via phosphorimaging. The intensity of the resulting bands was quantified with Kodak 1D image analysis software. The amount of GST and GST-A36 used in the reaction was visualized by staining with SimplyBlue SafeStain (Invitrogen).
Immunofluorescence analysis. HeLa cells were grown on coverslips and infected with vB5R-GFP, vB5R-GFP/F12L-HA, vB5R-GFP/F12L
⌬351-458
-HA, or vB5R-GFP/⌬F12L at a multiplicity of infection (MOI) of 1. Coverslips were harvested 24 h p.i., fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde, and permeabilized with PBS containing 10% fetal bovine serum and 0.1% saponin. Fixed cells were stained with anti-HA monoclonal antibody (MAb; Covance), followed by Texas Red-conjugated anti-mouse MAb (Jackson Immunoresearch Laboratories). Coverslips were washed three times in PBS and mounted onto slides with Mowiol that contained 1 g of DAPI (4Ј,6Ј-diamidino-2-phenylindole; EM Sciences) to visualize DNA. To stain actin, permeabilized cells were incubated with 1 unit of Alexa Fluor 633 phalloidin (Molecular Probes) for 20 min at room temperature. To stain B5-GFP on the cell surface, fixed cells were stained without permeabilization using MAb 19C2 (11), followed by Texas Red-conjugated anti-rat MAb (Jackson Immunoresearch Laboratories). Cells were washed, incubated with 50 g of Hoechst dye/ml, and mounted onto slides with Mowiol. Images were captured by using a Leica DMIRB inverted fluorescence microscope as described previously (19) and overlaid using Adobe PhotoShop software.
Coimmunoprecipitation. Plasmids pA36R-V5, pA36R -V5, and pA36R
1-111 -V5 were gifts of Bernard Moss and have been described previously (23) . HeLa cells were infected with either vB5R-GFP, vB5R-GFP/F12L-HA, or vB5R-GFP/ F12L
-HA at an MOI of 5 in the presence or absence of 0.1 g of the drug rifampin (Sigma-Aldrich)/ml. Cells were transfected at 2 h p.i., with either pA36R-V5, A36R -V5, or A36R -V5 using Lipofectamine (Invitrogen) according to the manufacturer's instructions. At 24 h p.i., cells were harvested by scraping, lysed in radioimmunoprecipitation assay buffer (half-strength PBS, 1% Triton X-100, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, and 0.2 mM phenylmethylsulfonyl fluoride), and centrifuged for 10 min at 14,000 ϫ g to pellet nuclei. Supernatants were precleared with protein G-agarose (Calbiochem) for 2 h at 4°C and incubated with anti-HA MAb (Santa Cruz Biotechnology), followed by protein G-agarose (Calbiochem). Immune complexes were pelleted, washed three times in radioimmunoprecipitation assay buffer, boiled in protein loading buffer, and resolved by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and incubated with either an anti-V5 horseradish peroxidase (HRP)-conjugated MAb (Invitrogen) or an anti-HA MAb (Roche), followed by an HRP-conjugated anti-rat MAb (Jackson Immunoresearch Laboratories). Bound antibodies were detected by using chemiluminescence analysis (Pierce).
Alkaline carbonate extraction. HeLa cells were infected with either vB5R-GFP or vB5R-GFP/F12L-HA at an MOI of 10. At 24 h p.i., the cells were harvested by scraping, washed three times with PBS, and washed once with 100 mM NaCl. Cells were resuspended in 100 mM sodium carbonate (pH 11.5), homogenized by douncing, and incubated on ice for 30 min. The homogenate was centrifuged at 200,000 ϫ g for 60 min at 4°C to pellet the membranes. Supernatants were removed and saved for analysis. Pellets were resuspended in an equal volume of 100 mM sodium carbonate (pH 11.5). Both the pellets and the supernatants were analyzed by Western blotting for the presence of F12-HA using an anti-HA MAb (Roche Diagnostics), B5-GFP using an anti-GFP MAb (Covance), and actin using an anti-actin MAb (Rockland).
Triton X-114 partitioning and membrane isolation. Triton X-114 partitioning was performed as previously described (1) . Briefly, BS-C-1 cells were infected at an MOI of 10 with either vB5R-GFP or vB5R-GFP/F12L-HA. At 24 h p.i., the medium was removed, and the cells were lysed in cold 10 mM Tris-HCl (pH 7.4) containing 2% Triton X-114 and 150 mM NaCl for 15 min on ice. The lysates were centrifuged for 7 min at 14,000 ϫ g to remove nuclei and other insoluble material. Supernatants were layered onto a 6% sucrose cushion containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.06% Triton X-114 and warmed to 37°C until clouding occurred. The samples were centrifuged at 1,000 ϫ g for 10 min, and the aqueous and detergent phases were extracted and analyzed by Western blotting with an anti-HA MAb (Roche Diagnostics) to detect F12-HA, anti-GFP MAb (Covance) to detect B5-GFP, and anti-actin MAb (Rockland) to detect actin as described above.
To isolate membranes, HeLa cells were infected with either vB5R-GFP, vB5R-GFP/F12L-HA, or vB5R-GFP/F12L
⌬351-458 -HA at an MOI of 10. At 24 h p.i., the medium was removed, and the cells were incubated in homogenization buffer (0.25 mM sucrose, 10 mM HEPES, 1 mM EDTA [pH 7.4]) containing protease inhibitor cocktail tablets (Roche Diagnostics) on ice for 20 min. Cells were disrupted by passage through a 27G syringe needle. The resulting lysates were centrifuged at 2,400 ϫ g for 5 min to remove nuclei and insoluble material. Postnuclear lysates were centrifuged at 200,000 ϫ g for 30 min at 4°C to pellet membranes. Supernatants were removed for analysis, and membrane pellets were suspended in an equal volume of PBS. Membrane pellets and supernatants were analyzed by Western blotting for the presence of F12-HA using an anti-HA MAb (Roche Diagnostics), B5-GFP using an anti-GFP MAb (Covance), and actin using an anti-actin MAb (Rockland).
RESULTS

F12 is not an integral membrane protein.
F12 is a 65-kDa protein that was shown to localize to IEV (18) . Initially, we wanted to determine whether F12 is a membrane-associated or an integral membrane protein. To do this, we constructed a recombinant vaccinia virus that replaced the normal copy of F12L with one that contained the coding sequence for a Cterminal HA epitope tag. An identical construct was previously shown to functionally replace the normal F12 (25) . Much like vB5R-GFP (22), our new recombinant, vB5R-GFP/F12L-HA, expressed a B5-GFP fusion protein to visualize and monitor morphogenesis at a subcellular level. Lysates were prepared from cells infected with either vB5R-GFP or vB5R-GFP/F12L-HA, and membranes in the lysates were pelleted by ultracentrifugation. The resulting supernatant and pellets were analyzed for the presence of F12-HA using Western blots. The anti-HA MAb specifically reacted with a ϳ64-kDa band that was present predominantly in the pellet from cells infected with vB5R-GFP/F12L-HA, which was absent in preparations from cells infected with vB5R-GFP (Fig. 1A) . Furthermore, the integral membrane protein B5-GFP was found almost entirely in the pellet from both infections. These results demonstrate that F12 is associated with membranes.
The amino acid sequence of F12 is not predicted to contain a transmembrane domain. It has been reported to contain two putative myristoylation sites at residues 129 and 551 (14) that may mediate its association with viral membranes. We used two standard assays, Triton X-114 partitioning and alkaline carbonate treatment, to determine whether F12 is a peripheral or an integral membrane protein. Lysates from cells infected with either vB5R-GFP or vB5R-GFP/F12L-HA were partitioned into two phases, aqueous and detergent, using Triton X-114 detergent, and each phase was analyzed for F12, actin and B5-GFP by using Western blotting. Both F12-HA and the soluble protein actin were predominantly in the aqueous phase, whereas the integral membrane protein B5-GFP was found in the detergent phase (Fig. 1B) , indicating that the majority of F12 does not have an integral association with membranes. Likewise, treatment of membranes with sodium carbonate extracted F12-HA so that it did not pellet with membranes, while B5-GFP was not extracted (Fig. 1B) . Both of these results indicate that the majority of F12 has a peripheral association with membranes. It is not an integral membrane protein nor does it associate with membranes through lipidation.
Residues 351 to 458 of F12 interact with the cytoplasmic domain of A36 in a yeast two-hybrid assay. The previous results indicated that F12 is not an integral membrane protein.
We hypothesized that F12 associates with membranes through an interaction with another IEV-specific, membrane-associated viral protein. To investigate this possibility, we used the yeast two-hybrid assay to look for interactions between F12 and the cytoplasmic domain of A33, A34, A36, and B5. In accordance with previous results, initial assays that used the full-length F12 fused to the Gal4 AD failed to detect an interaction (Table 1) (23) . This could be due to the inefficient expression of vaccinia virus proteins from the nucleus. In an effort to circumvent this problem, we tested truncations of F12 and found that residues 351 to 458 of F12 interacted with the cytoplasmic tail of A36 but not A33, A34, or B5 (Table 1) . In order to further define the region of A36 responsible for interaction with F12, we tested a series of previously constructed A36 truncations (23) . The results of these assays showed that residues 91 to 111 of A36 are sufficient for interaction with residues 351 to 458 of F12 (Table 2) .
To confirm the yeast two-hybrid results, we carried out an in vitro, GST pull-down assay. In agreement with previous results, one-step purification of either GST or GST-A36 
a QDO, quadruple-dropout medium. The amino acid ranges are indicated in parentheses. from Escherichia coli resulted in prominent bands of the predicted size for GST-A36
24-111 after SDS-PAGE (Fig. 2B ) (20) . Equal amounts of either GST or GST-A36 were determined by protein concentration assay and bound to glutathione-Sepharose beads. Bound beads were incubated with 35 Slabeled F12
351-458 or F12 1-121 as a negative control (Fig. 2C) . After extensive washing, complexes were eluted from the beads by boiling in SDS sample buffer and resolved by SDS-PAGE. Radiolabeled proteins were imaged with a phosphorimager. GST-A36 only bound F12 and not F12 ( Fig. 2A) . Importantly, neither bound an equivalent amount of GST, indicating that the interaction between F12 and A36 24-111 is specific for residues 351 to 458 of F12.
Interaction of F12 and A36 in infected cells. We next wanted to determine whether F12 and A36 could interact in infected cells. We constructed two additional recombinant vaccinia viruses: vB5R-GFP/F12L
⌬351-458
-HA and vB5R-GFP/⌬F12L. Both viruses express B5-GFP to visualize morphogenesis. The recom- -HA expresses an F12 that lacks residues 351 to 458 and has a C-terminal HA epitope tag. To ensure that equal amounts of F12-HA and F12
-HA were expressed, lysates from cells infected with the recombinant viruses were analyzed by Western blotting. Anti-HA MAb recognized proteins of the predicted size for F12-HA and F12
-HA (64 and 51 kDa, respectively) indicating that both HA-tagged proteins were stable and expressed at similar levels (Fig. 3A) .
Yeast two-hybrid and in vitro pull-down assays indicated that residues 351 to 458 of F12 interact with residues 91 to 111 of A36. We predicted that the interaction between F12 and A36 is responsible for the localization of F12 to IEV. To test this prediction, we confirmed the interaction between these proteins during infection. HeLa cells infected with vB5R-GFP, vB5R-GFP/F12L-HA, or vB5R-GFP/F12L
-HA were transfected with pA36R-V5, which expresses A36 with a V5 epitope tag. Lysates from cells infected with the recombinants were immunoprecipitated with an anti-HA MAb, and A36 was detected by Western blotting with anti-V5 HRP-conjugated MAb. In cells that expressed A36-V5 and F12-HA, A36-V5 was brought down by anti-HA MAb (Fig. 3B) , which confirmed that F12 and A36 interact in infected cells. Importantly, A36-V5 was not immunoprecipitated in cells expressing F12
-HA, confirming that residues 351 to 458 of F12 are necessary for the interaction. In addition, we performed immunoprecipitation to ensure that the anti-HA MAb immunoprecipitated equivalent amounts of F12-HA and F12
-HA (Fig. 3B) . To test whether residues 91 to 111 of A36 are involved in the interaction, we repeated the coimmunoprecipitation using two other plasmids that express A36-V5 truncations. Plasmids pA36R 1-111 -V5 and pA36R 1-80 -V5 express V5 epitope tagged versions of A36 that either contain or lack residues 91 to 111, respectively. In cells expressing F12-HA, only A36 1-111 -V5 was brought down by the anti-HA antibody (Fig. 3C) , confirming that residues 91 to 111 of A36 are required for interaction with F12 during infection.
Growth and spread of recombinant viruses. Plaque size is directly related to the amount of infectious CEV/EEV produced. Mutations that affect CEV/EEV production typically have a reduced plaque size. To look at the effect disruption of the F12:A36 interaction has on CEV/EEV production, we looked at the size of the plaques produced by our recombinants on monolayers of BS-C-1 cells. As had been reported previously (25) , the addition of an HA epitope tag to the C terminus of F12 had no significant effect on the size of plaques formed by vB5R-GFP/F12L-HA (Fig. 4) . In contrast, vB5R-GFP/F12L
-HA produced small plaques that were similar in size to vB5R-GFP/⌬F12L (Fig. 4) , suggesting that these two recombinants were defective in infectious extracellular virus production.
Low-MOI growth curves were performed to assess the ability of our recombinants to spread cell to cell, which is directly related to infectious CEV/EEV production. Cells infected with vB5R-GFP/F12L
⌬351-458 -HA and vB5R-GFP/⌬F12L released similar amounts of infectious virions that were ϳ2.5 logs less than vB5R-GFP/F12L-HA (Fig. 5A) . The amount of cellassociated infectious virus was also significantly less for vB5R-GFP/F12L
⌬351-458 -HA and vB5R-GFP/⌬F12L than for vB5R-GFP/F12L-HA (Fig. 5B) . In contrast, there was little difference in cell-associated virus over the same time period for all three recombinants when a high MOI was used, indicating that IMV production was unaffected (data not shown). These results indicate that the interaction of F12 with A36 is required for efficient CEV/EEV release.
Fluorescence microscopy of cells infected with recombinant viruses. Previous reports have shown that cells infected with vB5R-GFP have a reproducible fluorescent pattern. Typically, there are three hallmarks of this pattern: an accumulation of B5-GFP in the juxtanuclear region, virion-sized particles labeled with B5-GFP, and an accumulation of signal at the peripheral extensions, or vertices, of the cell (Fig. 6, arrows) .
Mutations that disrupt CEV/IEV production typically result in a change in this pattern. To determine whether disruption of the F12-A36 interaction has an effect on enveloped virus formation, we examined cells infected with our recombinant viruses by using immunofluorescence microscopy. Examination of the B5-GFP staining pattern in cells infected with vB5R-GFP and vB5R-GFP/F12L-HA showed identical subcellular fluorescent patterns with GFP signal in the juxtanuclear region (site of wrapping), as well as at the cell vertices (Fig. 6, arrows) . In addition, B5-GFP staining can be seen throughout the cytoplasm. B5-GFP staining can also be seen in cells infected with vB5R-GFP/F12L
⌬351-458 -HA and vB5R-GFP/⌬F12L (Fig.  6 ). However, there is an absence of signal accumulation at the vertices (Fig. 6, arrows) . In addition, we looked at the localization of F12 in these cells. As had been reported previously (18) , F12 localizes to the cell periphery in infected cells (Fig. 6 ) and appears to colocalize with B5-GFP in the vertices (Fig. 6,  arrows) . In contrast, only diffuse F12-HA staining was seen in cells infected with vB5R-GFP/F12
⌬351-458 -HA (Fig. 6 ), indicating that there is a defect in morphogenesis and that F12 may be mistargeted when it is unable to interact with A36.
vB5R-GFP/F12L
⌬351-458 -HA is defective in IEV release. The deletion of F12 has been reported to affect the release of IEV from infected cells (18, 25) . During a normal infection, B5 is deposited into the plasma membrane as IEV are released from the cell. Mutations that reduce CEV/EEV production subsequently reduces the amount of B5 on the cell surface. To determine whether our recombinants have a similar defect, we stained the surface of cells infected with our recombinant viruses for B5. Cells infected with vB5R-GFP and vB5R-GFP/ F12L-HA had significant B5 staining on the surface (Fig. 7A) . In contrast, the amount of B5 was severely reduced or absent in cells infected with vB5R-GFP/F12L
⌬351-458 -HA and vB5R-GFP/⌬F12L (Fig. 7A) , suggesting a defect in IEV release.
In addition to B5 surface staining, actin tail formation serves as an indicator of CEV production because CEV on the surface of cells form actin tails to facilitate cell-to-cell movement. To confirm that the reduction of B5 on the cell surface corresponded to a reduction of CEV, we measured actin tail production in cells infected with our recombinant viruses by staining infected cells with Alexa Fluor 633 conjugated to phalloidin. Numerous actin tails were easily identified in cells infected with either vB5R-GFP or vB5R-GFP/F12L-HA (Fig.  7B and insets) . In contrast, we were unable to find actin tails in cells infected with vB5R-GFP/F12L
⌬351-458 -HA and vB5R-GFP/⌬F12L (Fig. 7B and insets) .
F12 and A36 fail to interact in the presence of rifampin. Our immunofluorescence results correlate well with previous studies and demonstrate that F12 predominantly localizes to the cell periphery and not at the site of wrapping (18) . The defect in localization suggests that virion morphogenesis may be required for F12 to interact with A36. To test this possibility, we repeated the coimmunoprecipitation experiments in the presence or absence of the drug rifampin, which inhibits virion morphogenesis (2). We were only able to detect an interaction between F12 and A36 in the absence of rifampin (Fig. 8) . Importantly, our F12 and A36 constructs were expressed in the presence or absence of the drug, indicating that IMV, and subsequently IEV, formation is required for F12 to interact with A36. -HA is present (Fig. 9) . Importantly, F12
⌬351-458
-HA is present at comparable amounts to F12-HA in postnuclear supernatants (Fig. 9) , demonstrating that the absence of F12
-HA on membranes is not due to a lack of expression of the protein. These data suggest that the deletion of resi- 
DISCUSSION
A previous report used immunoelectron microscopy to show that F12 is only found on IEV and absent from CEV or EEV (18) . F12 is not predicted to contain a transmembrane domain; therefore, its method of association with IEV was unclear. Furthermore, a recent review suggested that two putative myristoylation sites in F12 may be responsible for anchoring it to the outer membrane of IEV (14) . The results from our alkaline carbonate extraction and Triton X-114 partitioning experiments suggest that F12 interacts with IEV through a peripheral association and not an integral association, such as through an unidentified transmembrane domain or protein lipidation. We hypothesized that the association of F12 with IEV may be mediated by interaction with another IEV-specific, integral membrane protein. The results of a yeast two-hybrid screen revealed an interaction between residues 351 and 458 of F12 and the cytoplasmic domain of A36. Further analysis using the yeast two-hybrid system mapped the site of interaction on A36 to amino acids 91 to 111. These results were confirmed using an in vitro, GST pull-down assay.
In order to further characterize the A36:F12 interaction and its role during virion morphogenesis, we constructed a recombinant that had the identified region on F12 removed (vB5R-GFP/F12L
⌬351-458 -HA). Coimmunoprecipitation confirmed that F12 and A36 interact in infected cells and that residues 351 to 458 of F12 are required for the interaction. Likewise, transfection of plasmids expressing truncated versions of A36 confirmed that residues 91 to 111 of A36 are required for interaction with F12.
Phenotypic characterization of our recombinant viruses revealed that vB5R-GFP/F12L
⌬351-458 -HA appeared identical to vB5R-GFP/⌬F12L. Further analysis revealed that both recombinants produced less CEV and were abrogated for actin tail formation. In addition, there was a distinct difference in the subcellular localization of F12-HA and F12
⌬351-458 -HA. This is most likely due to the inability of F12 ⌬351-458 -HA to associate with A36 on the viral membrane. In corroboration of this notion, membranes isolated from cells infected with vB5R-GFP/F12L
⌬351-458 -HA were devoid of F12, suggesting that amino acids 351 to 458 are vital for the localization, and ultimate functioning, of F12 during virion egress.
The interaction of F12 and A36 seems logical since both proteins are found exclusively on the outermost membrane of IEV. It now appears that F12 accomplishes this localization by interacting with the IEV-exclusive, integral membrane protein A36. The mechanism by which A36 excludes itself from the inner membrane of IEV is unclear. A36 must interact with A33 for incorporation into the virion membrane (23) . Unlike A36, A33 is found in both IEV membranes. This localization results in its presence on CEV and EEV. A36 must, therefore, regulate its interaction with A33 to limit its incorporation to only the outer membrane of IEV. Further work is required to elucidate the mechanism of selective incorporation of A36 and F12 into these membranes.
Four proteins have now been shown to interact with A36. The cellular proteins kinesin and Nck interact with A36 for microtubule-based movement and actin tail formation, respectively (5, 20) . The cytoplasmic tail of the viral protein A33 interacts with A36, and this interaction is required for the incorporation of A36 into virion membranes (23) . We now report that A36 interacts with F12 and that this interaction is required for efficient CEV/ EEV formation, but a specific function for F12 has not been determined. All four of these proteins seem to bind within a narrow region of A36, residues 81 to 116, and studies have shown that the interaction of A36 is mutually exclusive to kinesin or A33 (20) . Similar studies have not been carried out to determine whether A36 is able to bind Nck and any of the other three proteins simultaneously. Even if the interaction of A36 with these four proteins is mutually exclusive, this does not preclude IEV from interacting with all of them simultaneously since undoubtedly there are multiple molecules of A36 on the outer membrane of each IEV. Each of these molecules could potentially interact with a different binding partner at the same time. Much more work is required to determine the spatial and temporal dynamics, along with the potential regulation for all of the proteins that interact with A36.
During characterization of our recombinants we noticed that the majority of F12 did not localize to the site of wrapping. This is unlike A36, which has been shown to colocalize with B5 at the site of wrapping (23) . This led us to hypothesize that F12 may not associate with A36 until after IEV are formed. Indeed, we were unable to detect an F12-A36 interaction in the presence of the drug rifampin, which prevents morphogenesis. This suggests that there is a regulation that prevents the interaction of F12 with A36 until after virions are formed. In addition, the lack of F12 at the site of wrapping indicates that it may not play a major role in envelopment. It is more likely that F12 is required for some aspect of IEV egress. While there has been much speculation about a role for F12, a specific function has not yet been reported.
